• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

软骨发育不全:发育、发病机制及治疗

Achondroplasia: Development, pathogenesis, and therapy.

作者信息

Ornitz David M, Legeai-Mallet Laurence

机构信息

Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, USA.

Imagine Institute, Inserm U1163, Université Paris Descartes, Service de Génétique, Hôpital Necker-Enfants Malades, AP-HP, Paris, France.

出版信息

Dev Dyn. 2017 Apr;246(4):291-309. doi: 10.1002/dvdy.24479. Epub 2017 Mar 2.

DOI:10.1002/dvdy.24479
PMID:27987249
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5354942/
Abstract

Autosomal dominant mutations in fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia (Ach), the most common form of dwarfism in humans, and related chondrodysplasia syndromes that include hypochondroplasia (Hch), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), and thanatophoric dysplasia (TD). FGFR3 is expressed in chondrocytes and mature osteoblasts where it functions to regulate bone growth. Analysis of the mutations in FGFR3 revealed increased signaling through a combination of mechanisms that include stabilization of the receptor, enhanced dimerization, and enhanced tyrosine kinase activity. Paradoxically, increased FGFR3 signaling profoundly suppresses proliferation and maturation of growth plate chondrocytes resulting in decreased growth plate size, reduced trabecular bone volume, and resulting decreased bone elongation. In this review, we discuss the molecular mechanisms that regulate growth plate chondrocytes, the pathogenesis of Ach, and therapeutic approaches that are being evaluated to improve endochondral bone growth in people with Ach and related conditions. Developmental Dynamics 246:291-309, 2017. © 2016 Wiley Periodicals, Inc.

摘要

成纤维细胞生长因子受体3(FGFR3)的常染色体显性突变会导致软骨发育不全(Ach),这是人类最常见的侏儒症形式,以及相关的软骨发育异常综合征,包括低软骨发育不全(Hch)、伴有发育迟缓与黑棘皮病的严重软骨发育不全(SADDAN)和致死性发育异常(TD)。FGFR3在软骨细胞和成熟成骨细胞中表达,其功能是调节骨骼生长。对FGFR3突变的分析表明,通过包括受体稳定、二聚化增强和酪氨酸激酶活性增强等多种机制的组合,信号传导增加。矛盾的是,FGFR3信号传导增加会深刻抑制生长板软骨细胞的增殖和成熟,导致生长板尺寸减小、小梁骨体积减少,进而导致骨伸长减少。在这篇综述中,我们讨论了调节生长板软骨细胞的分子机制、软骨发育不全的发病机制,以及正在评估的旨在改善软骨发育不全患者及相关病症患者软骨内骨生长的治疗方法。《发育动力学》246:291 - 309, 2017。© 2016威利期刊公司。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/5354942/4e32968e919d/nihms835671f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/5354942/9062c7a0d159/nihms835671f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/5354942/3b9b0e54ecd4/nihms835671f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/5354942/a0b0efe8e8c8/nihms835671f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/5354942/a1614900e7bd/nihms835671f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/5354942/4e32968e919d/nihms835671f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/5354942/9062c7a0d159/nihms835671f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/5354942/3b9b0e54ecd4/nihms835671f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/5354942/a0b0efe8e8c8/nihms835671f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/5354942/a1614900e7bd/nihms835671f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/5354942/4e32968e919d/nihms835671f5.jpg

相似文献

1
Achondroplasia: Development, pathogenesis, and therapy.软骨发育不全:发育、发病机制及治疗
Dev Dyn. 2017 Apr;246(4):291-309. doi: 10.1002/dvdy.24479. Epub 2017 Mar 2.
2
Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.突变型FGFR3的持续磷酸化是遗传性侏儒症的关键特征,并通过PLCγ激活的STAT1诱导ATDC5软骨生成细胞系发生凋亡。
Bone. 2007 Aug;41(2):273-81. doi: 10.1016/j.bone.2006.11.030. Epub 2007 Feb 9.
3
Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation.与 SADDAN 疾病相关的突变 FGFR3 通过 PLCγ1/Src 介导的桩蛋白过度磷酸化导致细胞骨架紊乱。
Int J Biochem Cell Biol. 2018 Feb;95:17-26. doi: 10.1016/j.biocel.2017.12.008. Epub 2017 Dec 11.
4
Mild achondroplasia/hypochondroplasia with acanthosis nigricans, normal development, and a p.Ser348Cys FGFR3 mutation.伴有黑棘皮病、发育正常且携带p.Ser348Cys FGFR3突变的轻度软骨发育不全/低软骨发育不全
Am J Med Genet A. 2017 Apr;173(4):1097-1101. doi: 10.1002/ajmg.a.38141. Epub 2017 Feb 9.
5
FGFR3 induces degradation of BMP type I receptor to regulate skeletal development.成纤维细胞生长因子受体3(FGFR3)诱导骨形态发生蛋白(BMP)I型受体降解以调节骨骼发育。
Biochim Biophys Acta. 2014 Jul;1843(7):1237-47. doi: 10.1016/j.bbamcr.2014.03.011. Epub 2014 Mar 20.
6
Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia.成纤维细胞生长因子受体 3(FGFR3)的组成性激活会破坏各种软骨发育不全模型中的初级纤毛长度和IFT20 转运。
Hum Mol Genet. 2018 Jan 1;27(1):1-13. doi: 10.1093/hmg/ddx374.
7
Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.导致软骨发育不全和致死性发育异常的突变对成纤维细胞生长因子受体3的分级激活。
Nat Genet. 1996 Jun;13(2):233-7. doi: 10.1038/ng0696-233.
8
[Cytokines in bone diseases. FGF receptor signaling and achondroplasia/hypochondroplasia].[骨疾病中的细胞因子。成纤维细胞生长因子受体信号传导与软骨发育不全/软骨发育低下]
Clin Calcium. 2010 Oct;20(10):1490-6.
9
Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.十六年过去了:当前对骨骼发育不良中成纤维细胞生长因子受体 3(FGFR3)信号的理解。
Hum Mutat. 2012 Jan;33(1):29-41. doi: 10.1002/humu.21636. Epub 2011 Nov 16.
10
Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.成骨不全症中 FGFR3 突变的双重效应导致骨龄延迟。
Bone. 2010 Nov;47(5):905-15. doi: 10.1016/j.bone.2010.07.020. Epub 2010 Jul 29.

引用本文的文献

1
Assessing the clinical relevance of MRI findings in adult achondroplasia patients with lumbar spinal stenosis.评估成年软骨发育不全性腰椎管狭窄症患者MRI检查结果的临床相关性。
Brain Spine. 2025 Jul 28;5:104374. doi: 10.1016/j.bas.2025.104374. eCollection 2025.
2
Integrating vosoritide therapy with limb surgery in paediatric patients with achondroplasia: real-life experiences.在软骨发育不全的儿科患者中将沃索瑞肽治疗与肢体手术相结合:真实生活经验
Orphanet J Rare Dis. 2025 Jul 17;20(1):369. doi: 10.1186/s13023-025-03853-7.
3
Coping and quality of life of parents of children with achondroplasia-a narrative review.

本文引用的文献

1
Elevated Fibroblast Growth Factor Signaling Is Critical for the Pathogenesis of the Dwarfism in Evc2/Limbin Mutant Mice.成纤维细胞生长因子信号升高对Evc2/Limbin突变小鼠侏儒症的发病机制至关重要。
PLoS Genet. 2016 Dec 27;12(12):e1006510. doi: 10.1371/journal.pgen.1006510. eCollection 2016 Dec.
2
Chondrocyte FGFR3 Regulates Bone Mass by Inhibiting Osteogenesis.软骨细胞FGFR3通过抑制成骨作用调节骨量。
J Biol Chem. 2016 Nov 25;291(48):24912-24921. doi: 10.1074/jbc.M116.730093. Epub 2016 Oct 11.
3
Height Outcome of Recombinant Human Growth Hormone Treatment in Achondroplasia Children: A Meta-Analysis.
软骨发育不全患儿家长的应对方式与生活质量——一项叙述性综述
Front Med (Lausanne). 2025 May 30;12:1500389. doi: 10.3389/fmed.2025.1500389. eCollection 2025.
4
Advances in the mechanism and therapies of achondroplasia.软骨发育不全的发病机制与治疗进展
Genes Dis. 2024 Sep 24;12(4):101436. doi: 10.1016/j.gendis.2024.101436. eCollection 2025 Jul.
5
Application of biodegradable implants in pediatric orthopedics: shifting from absorbable polymers to biodegradable metals.可生物降解植入物在小儿骨科中的应用:从可吸收聚合物向可生物降解金属的转变。
Bioact Mater. 2025 Apr 10;50:189-214. doi: 10.1016/j.bioactmat.2025.04.001. eCollection 2025 Aug.
6
Translational genomics of osteoarthritis in 1,962,069 individuals.1962069例个体骨关节炎的转化基因组学研究
Nature. 2025 Apr 9. doi: 10.1038/s41586-025-08771-z.
7
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia.TYRA-300,一种FGFR3选择性抑制剂,在两种由FGFR3驱动的软骨发育异常模型中促进骨骼生长。
JCI Insight. 2025 Apr 3;10(9). doi: 10.1172/jci.insight.189307. eCollection 2025 May 8.
8
Recommendations for management of infants and young children with achondroplasia: Does clinical practice align?软骨发育不全婴幼儿管理建议:临床实践是否一致?
Orphanet J Rare Dis. 2025 Mar 11;20(1):114. doi: 10.1186/s13023-025-03621-7.
9
Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia.在软骨发育不全的小鼠模型中,成纤维细胞生长因子受体3(Fgfr3)增强子缺失显著改善了所有骨骼特征。
J Clin Invest. 2025 Jan 16;135(2):e184929. doi: 10.1172/JCI184929.
10
The Crosstalk Between Cartilage and Bone in Skeletal Growth.骨骼生长过程中软骨与骨之间的相互作用
Biomedicines. 2024 Nov 21;12(12):2662. doi: 10.3390/biomedicines12122662.
重组人生长激素治疗软骨发育不全儿童的身高结局:一项荟萃分析。
Horm Res Paediatr. 2016;86(1):27-34. doi: 10.1159/000446958. Epub 2016 Jun 30.
4
SHOX Haploinsufficiency as a Cause of Syndromic and Nonsyndromic Short Stature.SHOX基因单倍剂量不足作为综合征性和非综合征性身材矮小的一个病因
Mol Syndromol. 2016 Apr;7(1):3-11. doi: 10.1159/000444596. Epub 2016 Mar 15.
5
Signaling pathways effecting crosstalk between cartilage and adjacent tissues: Seminars in cell and developmental biology: The biology and pathology of cartilage.影响软骨与相邻组织间串扰的信号通路:细胞与发育生物学专题研讨会:软骨的生物学与病理学。
Semin Cell Dev Biol. 2017 Feb;62:16-33. doi: 10.1016/j.semcdb.2016.05.007. Epub 2016 May 12.
6
A second family with CATSHL syndrome: Confirmatory report of another unique FGFR3 syndrome.第二例患有卡特什尔综合征的家族:另一独特的成纤维细胞生长因子受体3(FGFR3)综合征的确证报告。
Am J Med Genet A. 2016 Jul;170(7):1908-11. doi: 10.1002/ajmg.a.37676. Epub 2016 May 3.
7
Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.酪氨酸激酶抑制剂NVP-BGJ398在小鼠模型中可有效改善与FGFR3相关的侏儒症。
J Clin Invest. 2016 May 2;126(5):1871-84. doi: 10.1172/JCI83926. Epub 2016 Apr 11.
8
Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody.用人源单克隆抗体抑制成纤维细胞生长因子受体3依赖性肺腺癌
Dis Model Mech. 2016 May 1;9(5):563-71. doi: 10.1242/dmm.024760. Epub 2016 Apr 7.
9
FGF signaling in the osteoprogenitor lineage non-autonomously regulates postnatal chondrocyte proliferation and skeletal growth.成骨祖细胞谱系中的成纤维细胞生长因子(FGF)信号非自主调节出生后软骨细胞增殖和骨骼生长。
Development. 2016 May 15;143(10):1811-22. doi: 10.1242/dev.131722. Epub 2016 Apr 6.
10
Genetic insights into the mechanisms of Fgf signaling.成纤维细胞生长因子(Fgf)信号传导机制的遗传学见解。
Genes Dev. 2016 Apr 1;30(7):751-71. doi: 10.1101/gad.277137.115.